Feb 28, 01:59 PM
Cytokinetics ($CYTK) reported its fourth-quarter 2023 financial results, leading to a shift in sentiment on biotwitter due to its disease-modifying drug. CEO Robert Blum addressed M&A speculation, denying any ongoing sales process. Investors are concerned about the stock's performance post-earnings, with questions about the impact of comments on REMS and potential filings.
Written with ChatGPT (GPT-3).
Sources
Logical Thesis
That $CYTK exit ahead of ER and raise looking ok so far. -10% since https://t.co/ajBZjJk7n4
Sheep of Wall Street Vas right now. $CYTK https://t.co/6oP5YGmH8w
Persimmon Tree Investments$CYTK It’s always about the M&A or lack thereof… Biotech investors have only one thing on their mind. https://t.co/ffr1weueMw
Additional media
